Using a CB1 blocker to treat kidney disease
Official title: A CB1 Antagonist for Treatment of Kidney Disease
Funded at Makscientific, LLC · NIH-10922519 · Data updated 2026-11-12
This study is looking at a new treatment using a medication called AM6588 to see if it can help improve kidney function and reduce symptoms in people with chronic kidney disease, especially those with diabetes.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Makscientific, LLC NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $572,743 |
| NIH project number | 1R44DK139888-01 |
| Project ID | NIH-10922519 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with diabetic kidney disease or chronic kidney disease.
✕Less likely to help
Patients without diabetes or those with non-diabetic forms of kidney disease may not benefit from this research.
What this research studies
This research investigates the use of a CB1 receptor antagonist, AM6588, to treat chronic kidney disease (CKD), particularly diabetic kidney disease (DKD). The study aims to understand how blocking the CB1 receptor can improve kidney function and reduce symptoms like albuminuria and inflammation. By testing this treatment in rodent models of diabetes, researchers hope to demonstrate its effectiveness in slowing the progression of kidney damage. If successful, this approach could lead to new therapies for patients suffering from CKD.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that slows the progression of kidney disease and improves overall kidney function.
How similar studies have gone: Previous studies have shown promising results with similar approaches using CB1 antagonists in animal models, indicating potential for success in human applications.
Where this research is happening
-
Makscientific, LLC
Burlington, United States Active
Researchers
- Principal investigator: Alapafuja, Shakiru Olajire — Makscientific, LLC
- Study coordinator: Alapafuja, Shakiru Olajire
Related research
Other NIH-funded projects on the same topics.
-
Personalized CKD-MBD care using systems biology and AI
A patient-facing program aims to tailor mineral-balance therapy for people with chronic kidney disease by using a computer model and smart decision rules to predict who will respond best to treatments.
-
Mitigating DKA in people with type 1 diabetes and kidney disease using SGLT1/2 inhibitors
This project tests a new way to prevent dangerous diabetic ketoacidosis in people with type 1 diabetes and chronic kidney disease who are using SGLT inhibitors, by tracking ketones in real time and combining glucose-keton data for safer therapy.
-
Chronic Kidney Disease in Children: following young people as they grow up with CKD
A long-term study in kids with chronic kidney disease tracks kidney function and heart health as they transition into adulthood.
-
Chronic Kidney Disease in Children follow-up study
A long-term study that follows kids with kidney disease as they grow into young adults, collecting health data from home and official records.
-
KDARC: Building a research backbone to study aging and kidney disease
Aimed at creating a dedicated infrastructure to advance aging-related kidney disease research so clinicians can better care for older adults.
-
Malaria-related kidney injury and its link to chronic kidney disease in children
This grant looks at why some children who have malaria develop kidney injury and later chronic kidney disease, focusing on how severe malaria affects the kidneys over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.